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Myelodysplastic syndromes (MDS) are hematological malignancies characterized by ineffective 
hematopoiesis and increased apoptosis in the bone marrow, which cause peripheral cytopenia. 
Mitochondria are key regulators of apoptosis and a site of iron accumulation that favors reactive oxygen 
species (ROS) production with detrimental effects on cell survival. Although the energy metabolism 
could represent an attractive therapeutic target, it was poorly investigated in MDS. The purpose of the 
study was to analyze how the presence of myelodysplastic hematopoiesis, iron overload and chelation 
impact on mitochondrial metabolism. We compared energy balance, OxPhos activity and efficiency, lactic 
dehydrogenase activity and lipid peroxidation in mononuclear cells (MNCs), isolated from 38 MDS patients 
and 79 healthy controls. Our data show that ATP/AMP ratio is reduced during aging and even more in MDS 
due to a decreased OxPhos activity associated with an increment of lipid peroxidation. Moreover, the 
lactate fermentation enhancement was observed in MDS and elderly subjects, probably as an attempt to 
restore the energy balance. The biochemical alterations of MNCs from MDS patients have been partially 
restored by the in vitro iron chelation, while only slight effects were observed in the age-matched control 
samples. By contrast, the addition of iron chelators on MNCs from young healthy subjects determined a 
decrement in the OxPhos efficiency and an increment of lactate fermentation and lipid peroxidation. In 
summary, MDS-MNCs display an altered energy metabolism associated with increased oxidative stress, 
due to iron accumulation. This condition could be partially restored by iron chelation.
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases, characterized by a clonal and ineffec-
tive hematopoiesis, an increased apoptosis within the bone marrow and risk of transformation into acute myeloid 
leukemia (AML)1. MDS affect especially the elderly and are characterized by one or more cytopenias, mainly 
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anemia, often requiring red blood cell transfusions, potentially leading to iron overload. Retrospective studies 
suggest that iron overload, besides organ damage, decreases survival and increases the risk of evolution towards 
AML, although prospective data are lacking2,3.
Oxidative phosphorylation (OxPhos) is the metabolic pathway devoted to the ATP aerobic production4. Many 
catabolic biochemical processes, such as glycolysis, the citric acid cycle and, indirectly, beta oxidation, produce 
the reduced coenzymes NADH and FADH2, necessary to sustain the OxPhos activity5. In particular, the NADH 
and FADH2 electrons pass to oxygen, the final acceptor, through a series of respiratory complexes, which form 
the electron transport chain, located in the inner membrane of the mitochondrion. This system in coupled with 
formation of a proton gradient across the inner mitochondria membrane, which represents the driving force to 
produce ATP. When the oxygen consumption is perfectly coupled with the ATP synthesis, the system is very effi-
cient and the risk of reactive oxygen species (ROS) production is limited6. By contrast, when oxygen consumption 
is not finalized to energy production, the ROS production increases, determining oxidative stress7,8. Moreover, 
other mitochondrial functions, such as thermoregulation, regulation of apoptosis/cell proliferation, detoxification 
of dangerous compounds, heme and iron sulfur cluster biosynthesis, regulation of cellular redox state and regu-
lation of several second messengers, are involved in the production of free radicals, concurring to the increment 
of cellular oxidative stress. Among ROS, the superoxide radical (·O2-), which derives from the first single-electron 
reduction of molecular oxygen, displays low reactivity and toxicity, but may function as an important second 
messenger in the cell. ·O2- is then reduced to hydrogen peroxide (H2O2), which is highly reactive and reacts with 
partially reduced metal ions such as Fe3+ and Cu2+, producing an extremely powerful oxidant, the hydroxyl rad-
ical (OH·), via the Fenton’s reaction9,10.
Increased production of ROS is the hallmark of many tumors including myelodysplastic syndromes11. ROS are 
capable of damaging proteins, lipids and DNA. Although high levels of ROS promote DNA mutations and genetic 
instability, over the last 20 years a more nuanced view of the role of ROS in cancer has come to light. Specifically, 
cancer cells generate increased ROS that are capable of increasing tumorigenesis by activating signaling pathways 
that regulate cellular proliferation, metabolic alterations, and angiogenesis12,13. However, from a metabolic point 
of view, cancer cells are characterized by a fermentative glycolytic metabolism, even when oxygen is available 
(Warburg effect14). This increment of glucose intake appears not only as a source of energy production15 but also 
as a basis to obtain the building blocks necessary for rapid proliferation14.
Since, mitochondria dysfunction, oxidative stress, and iron overload appears as emerging key players of MDS 
pathogenesis and progression, the purpose of this study is to analyze the MDS energetic metabolism and its link 
with the oxidative stress and the iron overload. In particular, we investigated aerobic ATP production, glycolysis, 
mitochondrial efficiency and lipid peroxidation of mononuclear cells (MNCs) isolated from MDS patients, com-
paring the results obtained on MNCs from young and elderly healthy subjects. Moreover, we analyzed the same 
parameters after treatment with two iron chelators.
Results
Cellular energy status decreases in MDS mononuclear cells. The cellular energy status has been 
investigated in term of ATP/AMP ratio, which represents the balance between the available energy (ATP) and 
the utilized energy (AMP). The measured ATP derives both from anaerobic glycolysis and OxPhos metabolism. 
As reported in Fig. 1, ATP/AMP ratio progressively decreases from young controls (8–20 yrs) to adult controls 
(21–60 yrs) and to elderly controls (61–86 yrs). Interestingly, MDS subjects show an additional decrement of this 
ratio, indicating a further reduction of the energetic availability (young CTRL vs elderly CTRL p < 0.0001 and 
elderly CTRL vs MDS p < 0.0001). More in details, the ATP/AMP mean ratio ± SEM in young CTRL is 3.3 ± 0.2, 
in adult CTRL is 2.5 ± 0.2 and in elderly CTRL is 1.3 ± 0.1, while it is 0.2 ± 0.03 in MDS subjects.
OxPhos is defective in MDS mononuclear cells. To evaluate whether the decrement of ATP/AMP 
ratio in elderly and MDS subjects is due to a dysfunction of mitochondrial energy metabolism, we analyzed the 
OxPhos activity. Oxygen consumption have been assayed after stimulation with pyruvate/malate (P/M) or suc-
cinate, to stimulate the pathways composed by complexes I, III and IV or complexes II, III and IV, respectively.
As shown in Fig. 2 Panel A, the oxygen consumption increases progressively with age, and the respiration of 
MDS-MNCs appears no-significantly different from those of adult and elderly controls. Conversely, ATP synthesis 
is significantly reduced in elderly control and, less marked, in MDS with respect to young and adult, especially for 
the system composed by complexes I, III and IV (Fig. 2, Panel B), which is the most efficient pathway, but also the 
main ROS producer10. In details, the oxygen consumption, expressed as mean ± SEM, after stimulation with pyru-
vate/malate is 10.3 ± 0.7 in young CTRL, 14.3 ± 0.7 in adult CTRL, 18.9 ± 1.9 in elderly CTRL, and it is 15.3 ± 0.7 in 
MDS subjects. The oxygen consumption after stimulation with succinate is 8.8 ± 0.7 in young CTRL, 15.8 ± 1.6 in 
adult CTRL, 19.4 ± 1.9 in elderly CTRL, and 15.7 ± 1.7 in MDS subjects. Regarding the ATP synthesis, after stim-
ulation with pyruvate/malate we have observed an ATP production of about 28.5 ± 2.7 in young CTRL, 29.9 ± 2.7 
in adult CTRL, 12.6 ± 1.5 in elderly CTRL, and 16.6 ± 1.8 in MDS subjects; and after stimulation with succinate 
16.0 ± 1.2 in young CTRL, 15.9 ± 1 in adult CTRL, 12,5 ± 1 in elderly CTRL, and 11.2 ± 1.4 in MDS subjects.
In order to obtain a more precise picture of the mitochondrial efficiency, we calculated the P/O value, as the 
ratio between the produced ATP and the oxygen consumption (Fig. 2, Panel C). The P/O ratio is clearly reduced 
in elderly CTRL and MDS compared to young or adult CTRL. In particular, the P/O ratio in young CTRL is 
2.6 ± 0.1 for P/M and 1.5 ± 0.1 for succinate (similarly to the values reported in literature6), while in the other 
groups decreases parallel with the age: 2.3 ± 0.1 for adult CTRL, 1 ± 0.2 for elderly CTRL, 1.3 ± 0.1 for MDS, 
after P/M induction, and 1.4 ± 0.1 for adult CTRL, 0.9 ± 0.1 for elderly CTRL, 1 ± 0.1 for MDS, after succinate 
stimulation. Notably, the difference is again more pronounced in the presence of P/M compared to that obtained 
after succinate induction.
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Lactate fermentation is enhanced in MDS mononuclear cells. In order to evaluate the contribution 
of the anaerobic glycolysis to the cell energy status, we evaluated the lactate dehydrogenase (LDH) activity, which 
converts pyruvate to lactate, when oxygen is absent or in short supply. In our samples, LDH activity is higher in 
MDS and elderly CTRL, as compared to young and adult controls (p < 0.0001) (Fig. 3). More in details, in young 
CTRL the mean LDH activity ± SEM is 188.5 ± 8.7 mU/mg, in adult CTRL is 205.6 ± 15.9 mU/mg, in elderly 
CTRL is 281.7 ± 13.4 mU/mg and in MDS is 337 ± 9.6 mU/mg.
Oxidative stress is increased in mononuclear cells from MDS patients. Since the OxPhos ineffi-
ciency is linked to an increment of oxidative stress production, we have evaluated the MDA level, as a marker of 
lipid peroxidation. MDA levels increase in elderly controls compared to young controls and appear even higher 
in MDS samples: p < 0.001 for MDS vs elderly CTRL, p < 0.0001 for elderly CTRL vs adult CTRL, p < 0.0001 
for adult CTRL vs young CTRL. Going into details, the mean ± SEM MDA levels are: 1.2 ± 0.2 μM/mg in young 
CTRL, 4 ± 0.7 μM/mg in adult CTRL, 9.3 ± 0.6 μM/mg in elderly CTRL and 13.9 ± 1 μM/mg in MDS patients 
(Fig. 4).
Iron chelation partially restores the energy balance in MDS mononuclear cells. Since MDS 
patients display a high iron accumulation, which can contribute to the oxidative stress production and the con-
sequent alteration of energy metabolism, we have incubated MNCs, in vitro for 24 hours, with two iron chelators: 
deferasirox (DFX) or deferoxamine (DFO).
Regarding the energy balance, DFX and DFO determined a decrease in the ATP/AMP ratio in cells from 
young and elderly CTRL, more evident in the age range between 8–20 years old. Conversely, the treatment 
induced an increment of energy availability in MNCs from MDS patients, as shown in Fig. 5 Panel A. Moreover, 
DFX seems to be more efficient than DFO in increasing this ratio.
More in details, the ATP/AMP ratio decreases in young CTRL from a mean value of 3.19 ± 0.37 to 1.24 ± 0.13 
with DFX and 1.66 ± 0.23 with DFO (p < 0.0001 and p < 0.001, respectively). In elderly, it decreases from a mean 
value of 1.12 ± 0.08 to 0.87 ± 0.05 with DFX and 0.95 ± 0.06 with DFO (p < 0.05 only for DFX). By contrast, in 
MDS the ATP/AMP ratio increases significantly from 0.12 ± 0.01 to 0.33 ± 0.02 with DFX and 0.24 ± 0.01 with 
DFO (p < 0.0001 for both).
The negative effect on young healthy subjects could depend by the chelation of the iron necessary for the 
normal mitochondrial function. On the contrary, in MDS the iron chelation improved the mitochondrial activity 
highly damaged by excessive iron. This effect was extremely consistent from one sample to another (data not 
shown).
OxPhos improves in MDS after iron chelation. As expected, the improvement of the ATP/AMP ratio in 
MDS patients after iron chelation is associated to the increased efficiency of the mitochondrial respiration. After 
incubation with DFX or DFO, oxygen consumption decreased in MDS patients, after stimulation either with 
P/M or succinate, while ATP synthesis increased (Supplementary Fig. 1), indicating a better coupling of OxPhos 
machinery. This hypothesis is confirmed by the improvement of the P/O ratio in MDS with both DFX and DFO 
after stimulation with P/M or succinate. Conversely, the P/O ratio in the presence of two chelators decreased in 
healthy controls, justifying the impairment of the ATP/AMP ratio reported above. Interestingly, both the negative 
Figure 1. ATP/AMP ratio. ATP/AMP ratio in MNCs isolated from young healthy subjects (CTRL 8–20 yrs), 
adult healthy subjects (CTRL 21–60 yrs), elderly healthy subjects (CTRL 61–86 yrs) and MDS patients with iron 
overload. Each column represents the mean ± SEM. Data are analyzed by one-way ANOVA followed by Tukey’s 
multiple comparison test. **** indicates a significant difference for p < 0.0001 between MDS sample and the 
healthy controls.
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and the positive effect of chelators treatment are more evident on the OxPhos metabolism induced by pyruvate/
malate. More in details, the P/M P/O ratio decreases in young CTRL from 2.39 ± 0.04 to 1.54 ± 0.03 with DFX 
and 1.93 ± 0.03 with DFO (p < 0.0001 for both). In elderly healthy subjects, it decreases from a mean value of 
0.85 ± 0.06 to 0.68 ± 0.02 with DFX and 0.73 ± 0.03 with DFO (p < 0.05 only for DFX). In MDS, the P/M P/O 
ratio increases significantly from 1.04 ± 0.06 to 1.74 ± 0.14 with DFX and 1.44 ± 0.09 with DFO (p < 0.001 and 
p < 0,05, respectively). Regarding the succinate P/O ratio, the value in young subjects passes from 1.51 ± 0.05 
to 0.98 ± 0.01 with DFX and 1.15 ± 0.02 with DFO (p < 0.0001 for both). In the elderly subjects, it passes from 
1.01 ± 0.03 to 0.93 ± 0.04 with DFX and 0.96 ± 0.04 with DFO (no significant differences). In MDS MNCs, the 
P/O value increases from 1.01 ± 0.03 to 1.23 ± 0.03 with DFX and 1.17 ± 0.01 with DFO (p < 0.001 and p < 0.01, 
respectively).
Figure 2. Oxygen consumption, ATP synthesis and P/O value in the presence of pyruvate/malate or succinate. 
Panel A: Oxygen consumption after stimulation with pyruvate/malate (P/M) (light grey column) or succinate 
(dark gray) in MNCs isolated from young healthy subjects (CTRL 8–20 yrs, n = 18), adult healthy subjects 
(CTRL 21–60 yrs; n = 18), elderly healthy subjects (CTRL 61–86 yrs, n = 25) and MDS patients with iron 
overload (n = 22). Panel B: aerobic ATP synthesis after stimulation with P/M (light grey column) or succinate 
(dark gray) in MNCs isolated from young healthy subjects (CTRL 8–20 yrs, n = 18), adult healthy subjects 
(CTRL 21–60 yrs; n = 18), elderly healthy subjects (CTRL 61–86 yrs, n = 25) and MDS patients with iron 
overload (n = 22). Panel C: P/O ratio, as marker of OxPhos efficiency, in MNCs isolated from young healthy 
subjects (CTRL 8–20 yrs, n = 18), adult healthy subjects (CTRL 21–60 yrs; n = 18), elderly healthy subjects 
(CTRL 61–86 yrs, n = 25) and MDS patients with iron overload (n = 22). For each Panel, data are expressed as 
mean ± SEM. Data are analyzed by one-way ANOVA followed by Tukey’s multiple comparison test. *, **, ***, 
**** indicate a significant difference for p < 0.05, p < 0.01, p < 0.001, p < 0.0001, respectively, between MDS 
sample and the healthy controls.
Figure 3. LDH activity assay. LDH activity has been evaluated as marker of anaerobic glycolysis in MNCs 
isolated from young healthy subjects (CTRL 8–20 yrs, n = 18), adult healthy subjects (CTRL 21–60 yrs; n = 20), 
elderly healthy subjects (CTRL 61–86 yrs, n = 25) and MDS patients with iron overload (n = 16). Each column 
represents the mean ± SEM. Data are analyzed by one-way ANOVA followed by Tukey’s multiple comparison 
test. * indicates a significant difference for p < 0.05 between MDS and CTRL 61–86 yrs; **** indicates a 
significant difference for p < 0.0001 between MDS sample and the CTRL 8–20 or the CTRL 21–60.
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Anaerobic glycolysis decreases after iron chelation. As shown in Fig. 5, Panel D, after incubation 
with iron chelators, MNCs from MDS patients show a significant decrease in LDH activity (p < 0.0001 for DFX 
and p < 0.001 for DFO). Interestingly the reduction of LDH activity is more pronounced with DFX than DFO 
(p < 0.0001).
By contrast, LDH activity is marked increase in young control (p < 0.0001 for DFX and 0.01 for DFO) and 
shows a slight enhancement in elderly CTRL, significant only for DFX treatment (p < 0.05).
More in details, the LDH activity decreases in young CTRL from 176.3 ± 3.7 to 240.4 ± 11.4 with DFX and 
216.7 ± 6.6 with DFO. In elderly healthy subjects, the basal activity is 279.3 ± 4.7 and shifts to 300.2 ± 5.6 with 
DFX and 293.4 ± 6.6 with DFO. In MDS MNCs, the basal LDH activity is 332.7 ± 5.8, and passes to 274.6 ± 4 with 
DFX and 303 ± 5.4 with DFO.
Lipid peroxidation decreases after iron chelation in MDS. Analyzing the lipid peroxidation in 
response to iron chelating treatment, we have observed a significant decrement of MDA levels (p < 0.0001 for 
both DFX and DFO) (Fig. 5, Panel E). By contrast, there was a trend towards increasing MDA levels in healthy 
controls, although statistically significant only for young subject (p < 0.001 for DFX and p < 0.05 for DFO), prob-
ably because iron chelators induced an indirect damage to the respiratory chain by removing the necessary iron.
More in details, the MDA in young CTRL is 2.3 ± 0.5, 4.76 ± 0.4 with DFX and 4.2 ± 0.4 with DFO. In elderly 
healthy subjects, the basal value is 9.0 ± 0.4 and passes to 10.9 ± 0.7 with DFX and 10.4 ± 0.9 with DFO. In MDS 
MNCs, MDA basal value is 12.3 ± 0.4, 8.7 ± 0.2 with DFX and 9.5 ± 0.3 with DFO.
Correlation between mitochondrial dysfunction, disease characteristics and systemic iron 
overload. Finally, we tried to correlate our results both with the disease features and with the markers of 
systemic iron overload. In particular, we investigated hemoglobin (Hb) levels, bone marrow blast percentage, 
and R-IPSS. No significant correlation is found between our data and the parameters mentioned above for 
pre-treatment conditions. In particular, cellular ATP deficiency, lactate dehydrogenase activity, mitochondrial 
function and MDA levels are not associated with any disease feature. In addition, we have looked for links 
between our data and ferritin or transferrin saturation, finding a strong correlation between MDA and serum 
ferritin levels with a Pearson product-moment correlation coefficient (PCC) of 0.8 (data not shown).
Discussion
Myelodysplastic syndromes are a heterogeneous group of diseases characterized by increased apoptosis in the 
bone marrow. Many molecular alterations have been implicated in MDS pathogenesis16. However, most of them 
resulted in increased apoptosis and ineffective erythropoiesis in the bone marrow. Mitochondria could play a 
crucial role, being the key regulators of apoptosis. Several lines of evidences linked mitochondrial dysfunction to 
dyserythropoiesis, including animal models carrying mitochondrial DNA mutations17. In addition, mitochon-
drial DNA has been found to be frequently mutated in MDS18 and also nuclear-encoded mitochondrial proteins 
have been found to be altered19. Mitochondria are also sites of iron accumulation, a process that frequently occurs 
in MDS and that favors ROS production. ROS, in turn, can have detrimental effects on cell survival: they increase 
lipid peroxidation and organelle damage, leading to cell death20, but also can damage DNA, favoring genomic 
instability, which may contribute to leukemic evolution. Finally, and most importantly for our study, mitochon-
dria are considered the principal source of energy, being the site of OxPhos. Energy metabolism is known to be 
altered in cancer cells and it could represent an attracting therapeutic target, but little is known about energy 
metabolism in hematological malignancies, and especially in MDS. Schildgen et al.21 indirectly addressed this 
issue, demonstrating that the transcription rate of four pivotal subunits of the mitochondrial respiratory chain 
Figure 4. Lipid peroxidation evaluated through the malondialdehyde levels. Malondialdehyde (MDA) levels 
have been evaluated in MNCs isolated from young healthy subjects (CTRL 8–20 yrs, n = 18), adult healthy 
subjects (CTRL 21–60 yrs; n = 24), elderly healthy subjects (CTRL 61–86 yrs, n = 28) and MDS patients with 
iron overload (n = 30). Each column represents the mean ± SEM. Data are analyzed by one-way ANOVA 
followed by Tukey’s multiple comparison test. **** indicates a significant difference for p < 0.0001 between 
MDS sample and the heathy controls.
6Scientific RepoRtS |         (2020) 10:9156  | https://doi.org/10.1038/s41598-020-66162-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
in myelodysplastic CD34 + cells was reduced, and that the stoichiometry of mitochondrial mRNA was altered. 
However, at the best of our knowledge, no study has ever directly evaluated the energy metabolism of MDS cells. 
Therefore, we analyzed in detail the MDS energy metabolism, trying to link this aspect to oxidative stress and iron 
overload. In particular, we compared energy balance, anaerobic glycolysis rate, OxPhos activity and efficiency, 
and lipid peroxidation in MNCs from MDS patients, comparing the results to those obtained on healthy controls. 
Results show that, although the ATP/AMP ratio decreased proportionally to the aging, MNCs from MDS patients 
displayed an energy status lower in comparison to that of age-matched healthy subjects, suggesting an alteration 
in the energy balance. To understand the origins of this energy shortage, we analyzed the OxPhos metabolism 
induced by P/M or succinate, observing an increment of oxygen consumption, but a decrement of ATP synthesis, 
both in elderly healthy subjects and MDS patients in comparison to the young controls. This causes the progres-
sive impairment of the OxPhos efficiency, as indicated by the decrement of P/O value, both after P/M or succinate 
induction. This determines not only a reduction in energy synthesis, but also an increment in the oxidative stress, 
since the uncoupled respiration is associated to the reactive oxygen species (ROS) production, especially from 
complex I. Moreover, the impairment of aerobic energy metabolism is associated with an increment of lactate 
dehydrogenase (LDH) activity, both in MDS patients and in elderly subjects with respect to the younger control, 
suggesting an attempt to restore the energy balance.
Interestingly, despite the P/O values appear similar in MDS and elderly healthy subjects, MDS-MNCs display 
a very low energy status, which can be only partially justify by the OxPhos impairment. This apparent discrepancy 
could be explained by the high energy expenditure necessary to contrast the increment of oxidative stress produc-
tion, which characterized the MDS cells22.
On the other hand, our data demonstrate a higher lipid peroxidation in MDS samples in comparison to the 
age-matched control samples, which seem associated with the iron overload since the MDA level decreases signif-
icantly after the incubation with iron chelators. However, the low ATP/AMP ratio in MDS cells could be also due 
to an unbalance between the enzymatic activities that convert AMP in ADP and ATP, and vice versa, such as the 
adenylate kinase family23 or by the increment of inflammatory processes associated to the iron overload. Further 
experiments will be necessary to investigate this topic24.
Figure 5. Evaluation of energy metabolism and lipid peroxidation after the treatment with iron chelators. 
Each Panel represents the data obtained on MNCs treated for iron chelation with deferasirox (DFX, light 
grey column) or deferoxamine (DFO, grey column). BASAL is for untreated samples (black column). Panel 
A: ATP/AMP ratio in MNCs isolated from young controls (CTRL 8–20 yrs, n = 9), elderly controls (CTRL 
61–86 yrs, n = 7) and MDS patients (MDS, n = 19). Panel B: P/O ratio after stimulation with pyruvate/malate 
(P/M) in MNCs isolated from young controls (CTRL 8–20 yrs, n = 9), elderly controls (CTRL 61–86 yrs, n = 7) 
and MDS patients (MDS, n = 19). Panel C: P/O ratio after stimulation with succinate in MNCs isolated from 
young controls (CTRL 8–20 yrs, n = 9), elderly controls (CTRL 61–86 yrs, n = 7) and MDS patients (MDS, 
n = 19). Panel D: LDH activity in MNCs isolated from young controls (CTRL 8–20 yrs, n = 9), elderly controls 
(CTRL 61–86 yrs, n = 7) and MDS patients (MDS, n = 19). Panel E: MDA levels in MNCs isolated from young 
controls (CTRL 8–20 yrs, n = 9), elderly controls (CTRL 61–86 yrs, n = 7) and MDS patients (MDS, n = 19). 
Each column represents the mean ± SEM. Data are analyzed by one-way ANOVA followed by Tukey’s multiple 
comparison test. *, **, ***, **** indicate a significant difference for p < 0.05, 0.01, 0.001 or 0.0001, respectively, 
between the untreated sample and the MNCs treated with iron chelators.
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The involvement of iron overload in the unbalance of energy metabolism is confirmed by the positive effects 
on MDS-MNCs after the in vitro treatment with two different iron chelators, deferasirox and deferoxamine. In 
particular, iron chelators were able to improve the ATP/AMP ratio, to restore partially the mitochondrial func-
tion, and to reduce the MDA level. Interestingly, the effects of iron chelation on healthy controls were opposite, 
especially for younger subjects, provoking a reduction of mitochondrial activity and ATP/AMP ratio, probably 
because the chelation removed the iron necessary for the activity of respiratory complexes cytochromes. Finally, 
no significant correlation was found between clinical parameters and energy metabolism except one: serum 
ferritin levels correlated with MDA production thus confirming the detrimental role of iron overload in lipid 
peroxidation.
In summary, our data show that MDS cells display an altered mitochondrial metabolism associated with an 
uncontrolled oxidative stress production, which determines a strong energy deficiency. This seems correlated 
with the iron overload, as suggested by the partial restoring of the MDS-MNCs energy metabolism after iron 
chelation treatment.
Material and Methods
The FISM-BIOFER 12 study has been approved by the local ethic committee San Luigi Gonzaga (number of 
approval: 14/2013). All methods were performed in accordance with the relevant guidelines and regulations. Ten 
centers participated into the study. This prospective study enrolled MDS patients with transfusion dependent iron 
overload. Peripheral Blood (PB) samples were collected at the time of starting iron chelation therapy (ICT). After 
UPN Diagnosis age R-IPSS Cytogenetic
serum 
ferritin
1 MDS-MLD 80 low normal 2400
2 MDS-MLD 79 int normal 1460
3 MDS-MLD 67 low normal 280
4 MDS-MLD 78 int trisomy 8 2800
5 MDS-MLD 80 low normal 5220
6 MDS-MLD 79 low normal 4870
7 MDS-MLD 69 int del(7q) 890
8 MDS-EB-2 79 very high del(7q) 4800
9 MDS-EB-2 84 very high normal NA
10 MDS-EB-1 74 high del(20q) 1450
11 MDS-EB-1 81 int normal 1090
12 MDS-EB-1 76 NA NA 12800
13 MDS-EB-1 77 high normal 2760
14 MDS-EB-1 77 int normal 1700
15 MDS-EB-1 76 Int normal 6670
16 MDS-SLD 80 low normal 6520
17 MDS-SLD 85 low normal 2400
18 MDS-SLD 74 low normal 3380
19 MDS-SLD 61 int del(7q) NA
20 MDS-SLD 65 low normal 2230
21 MDS-SLD 86 low normal 7400
22 MDS-SLD 75 int trisomy 8 1800
23 MDS-SLD 77 int normal 4700
24 MDS-SLD 77 int −7 NA
25 MDS-SLD 67 NA NA 5240
26 MDS-SLD 75 low normal 7400
27 MDS-SLD 73 very low del(11q) 1700
28 MDS-SLD 80 low normal 4000
29 MDS-SLD 83 NA NA 6440
30 MDS-SLD 69 low normal 2100
31 MDS-SLD 72 low normal 1420
32 MDS-SLD 68 NA NA 2270
33 MDS-SLD 68 verylow normal 1380
34 del(5q) 57 very low del(5q) 3670
35 MDS-SLD 73 low normal 1820
36 MDS-SLD 84 NA NA 2770
37 MDS-EB-1 82 high normal 1889
38 MDS-EB-2 65 Very high complex 3880
Table 1. Clinical characteristics of the MDS patients.
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written informed consent, PB samples from 38 MDS patients, and 79 healthy controls have been collected. Not 
every sample could be analyzed for all the experiments described below, mainly because of peripheral cytopenia.
Normal controls (CTRL) are divided into the following age groups: 22 young controls (mean age 12 yrs ± 
2.9), 24 adult controls (mean age 38 yrs ±12.2) and 33 elderly controls (mean age 73 yrs ±8.4). MDS risk was 
classified according to the Revised International Prognostic Scoring System (R-IPSS)24. According to the WHO 
classification, the MDS group included: 20 MDS with single lineage dysplasia (MDS-SLD), 7 MDS with multilin-
eage dysplasia (MDS-MLD), 7 refractory anemia with excess of blasts type I (RAEB-I), 3 RAEB II and 1 case of 
isolated 5q-. All MDS sample came from patients with high level of iron before being included in a protocol with 
iron chelation treatment. The general characteristics of these patients are summarized in Table 1. The mean age 
of the MDS patients was 75 ± 6.8.
Mononuclear cells isolation. Mononuclear cells (MNCs) were isolated from 10 ml of PB on a Ficoll gradi-
ent. All samples were sent to the laboratory and analysed within 24 hours from collection.
Iron chelation. 16 PB from healthy controls (7 young subjects with a mean age of 17 ± 3.6, 9 elderly subjects 
with a mean age 67 ± 5.5) and 19 myelodysplastic patients with a mean age 72 ± 8.4) were incubated with two iron 
chelators: Deferasirox (DFX) and Deferoxamine (DFO), for 24 hours, both at 50 uM concentration25.
All myelodysplastic patients have an iron overload due to blood transfusions with a serum ferritin level higher 
than 1000 ng/mL and a transferrin saturation higher than 70% and all of them have received at least 20 U of red 
blood cells. All samples were taken before starting iron chelation therapy.
Evaluation of ATP/AMP intracellular level, lipid peroxidation and Lactate dehydrogenase (LDH) 
assays. ATP and AMP were measured according to the enzyme coupling method, following the NADP reduc-
tion or NADH oxidation, at 340 nm, respectively26. To assess lipid peroxidation, the malondialdehyde (MDA) 
level was evaluated by the thiobarbituric acid reactive substances (TBARS) test, at 532 nm26. LDH activity was 
measured as marker of anaerobic glycolysis following the NADH oxidation, at 340 nm26.
Oxygen consumption measurements. Oxygen consumption was measured in a closed chamber, using 
an amperometric electrode (Unisense-Microrespiration, Unisense A/S, Denmark)27.100,000 cells, permeabilized 
with 0.03% digitonin for 1 min were used for each experiment. Pyruvate and malate were used to stimulate the 
pathway composed by complexes I, III and IV, while succinate induced the pathway formed by complexes II, III 
and IV. To observe the ADP-stimulated respiration rates, 0.08 mM ADP was added after pyruvate and malate or 
succinate addition.
Fo F1 ATP synthase activity. ATP synthesis, trough Fo-F1 ATP synthase, was performed according to 
published method28.The reaction was monitored in a luminometer (GloMax® 20/20n Luminometer, Promega 
Italia, Milano, Italy), by the luciferin/luciferase chemiluminescent method, with ATP standard solutions between 
10–8 and 10–5 M (luciferin/luciferase ATP bioluminescence assay kit CLSII, Roche, Basel, Switzerland).
Evaluation of the efficiency of mitochondrial energy metabolism. The OxPhos efficiency (P/O 
ratio) was calculated as the ratio between the concentration of the produced ATP and the amount of consumed 
oxygen in the presence of respiratory substrate and ADP. When the oxygen consumption is completely devoted to 
the energy production, the P/O ratio should be around 2.5 and 1.5 after pyruvate + malate or succinate addition, 
respectively6,28.
Statistical analysis. Data were analyzed by one-way ANOVA followed by Tukey’s multiple comparison test, 
using GraphPad Prism version 7.00. P value <0.05 was considered significant.
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